BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

At present, MM is still an incurable disease in general, and the vast majority of patients will eventually face disease recurrence or progression. Although CAR-T therapy targeting BCMA has shown advantages in the efficacy and safety of MM, for MM patients with BCMA negative or BCMA low expression, they still relapse after receiving targeted BCMA CAR T-cell therapy, and there is a problem of target escape. The specific high expression of GPRC5D in multiple myeloma cells makes it possible to combine BCMA and GPRC5D in the treatment of MM. This study aims to investigate the safety and efficacy of BCMA-GPRC5D CAR-T therapy in the treatment of relapsed or refractory MM.

NCT Number	NCT06644443
Lead Sponsor	Shenzhen University General Hospital
Conditions	Multiple Myeloma in Relapse
Enrollment	10 participants
Start Date	2023-07-15
Primary Completion	2025-07-14 (estimated)
Study Completion	2026-07-14 (estimated)
Updated on ClinicalTrials.gov	2024-10-16